InterMune Ad Improperly Infers Infergen Superiority, FDA’s Ad Division Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A DDMAC untitled letter accuses InterMune of overstating efficacy and omitting safety information in an ad for chronic hepatitis C therapy Infergen.